Torrent Pharmaceuticals Ltd.
http://www.torrentpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Torrent Pharmaceuticals Ltd.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Stake Sale Speculation At Two PE-Controlled Firms In India: Will Valuations Fly?
Two top-50 Indian firms are speculated to be on the block with valuations expected to be richer than past multiples paid by buyers. A small, less known life sciences solutions provider is also keen to rope in a CDMO partner. Scrip speaks to a cross-section of experts on the action in deal street.
Torrent Spells Out Ambitions For $300m Business In The US
India’s Torrent underlined that it had no plans of decreasing its commitment to the US market, while plotting continued growth in India and Germany, as it delivered financial results for its 2023/24 financial year.
Amid Talk Of KKR Stake Sale, JB CEO Stresses Business As Usual
In an interview with JB CEO Nikhil Chopra, Scrip discusses talk of a stake sale by private equity fund KKR, gains from acquisitions including select Novartis brands, plans to ascend to the top five in cardiology and a ramp up of the CDMO business, which has clients including J&J.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Unichem Laboratories Ltd.
- Bio-Pharm, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice